PURPOSE: Patient engagement in multiple sclerosis (MS) care can be challenging at times given the unpredictable disease course, wide range of symptoms, variable therapeutic response to treatment and high rates of patient depression. Patient activation, a model for conceptualising patients' involvement in their health care, has been found useful for discerning patient differences in chronic illness management. The purpose of this study was to validate the patient activation measure (PAM-13) in an MS clinic sample. METHODS: This was a survey study of 199 MS clinic patients. Participants completed the PAM-13 along with measures of MS medication adherence, self-efficacy, depression and quality of life. RESULTS: Results from Rasch and correlation analyses indicate that the PAM-13 is reliable and valid for the MS population. Activation was associated with MS self-efficacy, depression and quality of life but not with self-reported medication adherence. Also, participants with relapse-remitting MS, current employment, or high levels of education were more activated than other subgroups. CONCLUSIONS: The PAM-13 is a useful tool for understanding health behaviours in MS. The findings of this study support further clinical consideration and investigation into developing interventions to increase patient activation and improve health outcomes in MS.
PURPOSE:Patient engagement in multiple sclerosis (MS) care can be challenging at times given the unpredictable disease course, wide range of symptoms, variable therapeutic response to treatment and high rates of patientdepression. Patient activation, a model for conceptualising patients' involvement in their health care, has been found useful for discerning patient differences in chronic illness management. The purpose of this study was to validate the patient activation measure (PAM-13) in an MS clinic sample. METHODS: This was a survey study of 199 MS clinic patients. Participants completed the PAM-13 along with measures of MS medication adherence, self-efficacy, depression and quality of life. RESULTS: Results from Rasch and correlation analyses indicate that the PAM-13 is reliable and valid for the MS population. Activation was associated with MS self-efficacy, depression and quality of life but not with self-reported medication adherence. Also, participants with relapse-remitting MS, current employment, or high levels of education were more activated than other subgroups. CONCLUSIONS: The PAM-13 is a useful tool for understanding health behaviours in MS. The findings of this study support further clinical consideration and investigation into developing interventions to increase patient activation and improve health outcomes in MS.
Authors: Brian W Pennarola; Angie Mae Rodday; Deborah K Mayer; Sara J Ratichek; Stella M Davies; Karen L Syrjala; Sunita Patel; Kristin Bingen; Mary Jo Kupst; Lisa Schwartz; Eva C Guinan; Judith H Hibbard; Susan K Parsons Journal: Med Care Res Rev Date: 2011-12-26 Impact factor: 3.929
Authors: Bi Xia Ngooi; Tanya L Packer; George Kephart; Grace Warner; Karen Wei Ling Koh; Raymond Ching Chiew Wong; Serene Peiying Lim Journal: Qual Life Res Date: 2016-09-19 Impact factor: 4.147
Authors: Tanya L Packer; George Kephart; Setareh Ghahari; Åsa Audulv; Joan Versnel; Grace Warner Journal: Qual Life Res Date: 2015-01-06 Impact factor: 4.147
Authors: Suzanne E Mitchell; Paula M Gardiner; Ekaterina Sadikova; Jessica M Martin; Brian W Jack; Judith H Hibbard; Michael K Paasche-Orlow Journal: J Gen Intern Med Date: 2013-10-04 Impact factor: 5.128
Authors: Nwamaka D Eneanya; Michael Winter; Howard Cabral; Katherine Waite; Lori Henault; Timothy Bickmore; Amresh Hanchate; Michael Wolf; Michael K Paasche-Orlow Journal: J Health Care Poor Underserved Date: 2016
Authors: Rebecca Marshall; Mary Catherine Beach; Somnath Saha; Tomi Mori; Mark O Loveless; Judith H Hibbard; Jonathan A Cohn; Victoria L Sharp; P Todd Korthuis Journal: J Gen Intern Med Date: 2013-05 Impact factor: 5.128
Authors: Robert G Nelson; V Shane Pankratz; Donica M Ghahate; Jeanette Bobelu; Thomas Faber; Vallabh O Shah Journal: Clin J Am Soc Nephrol Date: 2018-11-15 Impact factor: 8.237